Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of "Buy" by Analysts

Key Points

• Analyst consensus: Buy — 11 analysts cover MAZE (1 sell, 8 buy, 2 strong buy) with an average 12‑month target of $66.00.
• Trading and fundamentals: Maze has a market cap of about $1.36B, a negative P/E (-8.44), a 1‑year range of $8.24–$53.65, and reported Q1 EPS of -$0.65 (beating estimates by $0.08); analysts project ~-2.59 EPS for the fiscal year.
• Insider and institutional activity: insiders sold a total of 70,000 shares (~$2,955,775) in the last 90 days under Rule 10b5‑1 plans, while several institutions modestly increased positions.

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been given a consensus rating of "Buy" by the eleven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $66.00.

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reiterated a "sell (d)" rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Wedbush upped their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an "outperform" rating in a report on Monday, March 16th. Guggenheim upped their price target on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a "buy" rating in a report on Wednesday, March 4th. JPMorgan Chase & Co. upped their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an "overweight" rating in a report on Tuesday, March 31st. Finally, BTIG Research restated a "buy" rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, March 25th.

Maze Therapeutics Trading Up 0.4%

Shares of NASDAQ:MAZE opened at $27.27 on Monday. The stock has a market capitalization of $1.36 billion, a PE ratio of -8.44 and a beta of 2.50. Maze Therapeutics has a 1 year low of $8.24 and a 1 year high of $53.65. The firm has a fifty day moving average price of $36.92 and a 200 day moving average price of $38.18.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.08. On average, sell-side analysts forecast that Maze Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, SVP Amy Bachrodt sold 2,500 shares of the company's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $29.44, for a total transaction of $73,600.00. Following the completion of the sale, the senior vice president directly owned 12,965 shares in the company, valued at $381,689.60. This represents a 16.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the company's stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total transaction of $190,275.00. Following the sale, the insider owned 10,503 shares of the company's stock, valued at $266,461.11. This trade represents a 41.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 70,000 shares of company stock worth $2,955,775 over the last ninety days.

Institutional Investors Weigh In On Maze Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Royal Bank of Canada raised its position in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock valued at $27,000 after buying an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after buying an additional 738 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock valued at $55,000 after buying an additional 766 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its position in shares of Maze Therapeutics by 18.5% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company's stock valued at $247,000 after buying an additional 931 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Maze Therapeutics during the fourth quarter valued at about $39,000.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.